Blueprint Medicines Corp Stock Price Prediction
| BPMC Stock | USD 89.58 0.26 0.29% |
Momentum 36
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.43) | EPS Estimate Current Year (1.28) | EPS Estimate Next Year 1.4117 | Wall Street Target Price 127.2222 | EPS Estimate Current Quarter (0.71) |
Using Blueprint Medicines hype-based prediction, you can estimate the value of Blueprint Medicines Corp from the perspective of Blueprint Medicines response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Blueprint Medicines using Blueprint Medicines' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Blueprint using crowd psychology based on the activity and movement of Blueprint Medicines' stock price.
Blueprint Medicines Short Interest
A significant increase or decrease in Blueprint Medicines' short interest from the previous month could be a good indicator of investor sentiment towards Blueprint. Short interest can provide insight into the potential direction of Blueprint Medicines stock and how bullish or bearish investors feel about the market overall.
200 Day MA 97.4643 | Short Percent 0.0829 | Short Ratio 4.62 | Shares Short Prior Month 4.2 M | 50 Day MA 98.8973 |
Blueprint Medicines Corp Hype to Price Pattern
Investor biases related to Blueprint Medicines' public news can be used to forecast risks associated with an investment in Blueprint. The trend in average sentiment can be used to explain how an investor holding Blueprint can time the market purely based on public headlines and social activities around Blueprint Medicines Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Blueprint Medicines' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Blueprint Medicines.
Blueprint Medicines Implied Volatility | 0.59 |
Blueprint Medicines' implied volatility exposes the market's sentiment of Blueprint Medicines Corp stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Blueprint Medicines' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Blueprint Medicines stock will not fluctuate a lot when Blueprint Medicines' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Blueprint Medicines to buy its stock at a price that has no basis in reality. In that case, they are not buying Blueprint because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Blueprint Medicines after-hype prediction price | USD 89.51 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Blueprint contract
Based on the Rule 16, the options market is currently suggesting that Blueprint Medicines Corp will have an average daily up or down price movement of about 0.0369% per day over the life of the 2025-06-20 option contract. With Blueprint Medicines trading at USD 89.58, that is roughly USD 0.033 . If you think that the market is fully incorporating Blueprint Medicines' daily price movement you should consider acquiring Blueprint Medicines Corp options at the current volatility level of 0.59%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Blueprint |
Blueprint Medicines After-Hype Price Prediction Density Analysis
As far as predicting the price of Blueprint Medicines at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Blueprint Medicines or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Blueprint Medicines, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Blueprint Medicines Estimiated After-Hype Price Volatility
In the context of predicting Blueprint Medicines' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Blueprint Medicines' historical news coverage. Blueprint Medicines' after-hype downside and upside margins for the prediction period are 85.99 and 93.03, respectively. We have considered Blueprint Medicines' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Blueprint Medicines is very steady at this time. Analysis and calculation of next after-hype price of Blueprint Medicines Corp is based on 3 months time horizon.
Blueprint Medicines Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Blueprint Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Blueprint Medicines backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Blueprint Medicines, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.04 | 3.52 | 0.07 | 0.06 | 9 Events / Month | 8 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
89.58 | 89.51 | 0.08 |
|
Blueprint Medicines Hype Timeline
Blueprint Medicines Corp is currently traded for 89.58. The entity has historical hype elasticity of -0.07, and average elasticity to hype of competition of -0.06. Blueprint is expected to decline in value after the next headline, with the price expected to drop to 89.51. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.08%, whereas the daily expected return is currently at -0.04%. The volatility of related hype on Blueprint Medicines is about 252.54%, with the expected price after the next announcement by competition of 89.52. About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.07. Blueprint Medicines Corp had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 9 days. Check out Blueprint Medicines Basic Forecasting Models to cross-verify your projections.Blueprint Medicines Related Hype Analysis
Having access to credible news sources related to Blueprint Medicines' direct competition is more important than ever and may enhance your ability to predict Blueprint Medicines' future price movements. Getting to know how Blueprint Medicines' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Blueprint Medicines may potentially react to the hype associated with one of its peers.
Blueprint Medicines Additional Predictive Modules
Most predictive techniques to examine Blueprint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Blueprint using various technical indicators. When you analyze Blueprint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Blueprint Medicines Predictive Indicators
The successful prediction of Blueprint Medicines stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Blueprint Medicines Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Blueprint Medicines based on analysis of Blueprint Medicines hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Blueprint Medicines's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Blueprint Medicines's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 4.35 | 12.78 | 3.1 | 1.88 | Revenue Per Share | 3.42 | 4.12 | 8.09 | 8.5 |
Story Coverage note for Blueprint Medicines
The number of cover stories for Blueprint Medicines depends on current market conditions and Blueprint Medicines' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Blueprint Medicines is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Blueprint Medicines' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Blueprint Medicines Short Properties
Blueprint Medicines' future price predictability will typically decrease when Blueprint Medicines' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Blueprint Medicines Corp often depends not only on the future outlook of the potential Blueprint Medicines' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Blueprint Medicines' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.9 M | |
| Cash And Short Term Investments | 615.5 M |
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |